BP42573 An Open-Label, Multicenter, Phase I Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Clinical Activity of RO7428731 in Participants with Glioblastoma Expressing Mutant Epidermal Growth Factor Receptor Variant III (Aktiv)
GBM Agile GBM AGILE Global Adaptive Trial Master Protocol: An International, Seamless Phase II/III Response Adaptive Randomization Platform Trial Designed To Evaluate Multiple Regimens In Newly Diagnosed and Recurrent Glioblastoma (GBM) (Aktiv)
Erstlinie
Glio-XS15 Multi Peptide Vaccination With XS15 in Addition to Standard Postoperative Radiation Therapy and Temozolomide Chemotherapy in Newly Diagnosed Glioblastoma (Aktiv)
INTRAGO II A multicenter randomized Phase III Trial in INTraoperative RAdiotherapy in newly diagnosed GliOblastoam multiforme (INTRAGO II) (Aktiv)
RESURGE Surgery for Recurrent Glioblastoma (RESURGE) (Aktiv)
TRIDENT EF-32 EF-32: Pivotal, Randomized, Open-Label Study of Optune® (Tumor Treating Fields, 200kHz) Concomitant With Radiation Therapy and Temozolomide for the Treatment of Newly Diagnosed Glioblastoma (Aktiv)
Zweitlinie oder später
Car2Brain Intracranial Injection of NK-92/5.28.z (HER2.taNK) Cells in Patients With Recurrent HER2-positive Glioblastoma (Quilt 3.C001) (CAR2BRAIN) (Aktiv)
CureVav A Phase 1 Dose-Finding Study to Evaluate Safety and Tolerability of CVGBM in Patients with Surgically Resected Glioblastoma (GBM) or Astrocytoma with a Molecular Signature of Unmethylated Glioblastoma (Aktiv)
EOGBM1-18 First-in-Human, Phase 1b/2a Trial of a Multipeptide Therapeutic Vaccine in Patients With Progressive Glioblastoma (Aktiv)
GIRO Phase III Studie zur erneuten Bestrahlung mit Kohlenstoffionen oder Photonen als Zweitlinientherapie bei Glioblastom (Aktiv)
HIT-HGG-Rez-Immunovac Autologous Dendritic Cells and Metronomic Cyclophosphamide for Relapsed High-Grade Gliomas in Children and Adolescents HIT-HGG-Rez-Immunovac - A Clinical Phase I/II Trial of the HIT-HGG Study Group - (Aktiv)
MecMeth Phase I/II Studie zu Meclofenamate als Zweitlinientherapie bei Glioblastom-Rezidiv mit methyliertem MGMT-Promotor (Aktiv)
RESURGE Surgery for Recurrent Glioblastoma (RESURGE) (Aktiv)
VXM01-AVE-04-INT An open-label, Phase I/II multicenter clinical trial of VXM01 in combination with avelumab in patients with progressive glioblastoma following standard treatment with or without second surgery. (Aktiv)